TTY Biopharm Company Limited (4105)
TWSE
78.40
+0.60 (+0.77%)
Closed
Aug 26, 2026
Day's Range
77.7078.80
52 wk Range
71.6087.00
Financial Statements - 4105 - TTY Biopharm Company Limited
Revenue
6.45B▲ 9.5%
Net Income
1.65B▲ 8.9%Net Margin 25.6%
EBITDA
2.34B▲ 11.1%
Free Cash Flow
1.61B▲ 32.6%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 6.45B | 5.89B | 5.50B | 5.06B | 4.53B | 4.22B |
| Cost of Goods | 2.73B | 2.47B | 2.21B | 2.04B | 1.76B | 1.61B |
| Gross Profit | 3.72B | 3.41B | 3.28B | 3.02B | 2.76B | 2.60B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 1.70B | 1.39B | 1.37B | 1.23B | 1.15B | 955M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | - | - | - | - | - | - |
| Pre Tax Income | 2.12B | 1.88B | 1.41B | 1.40B | 1.08B | 1.20B |
| Income Tax | 470.47M | 366.33M | 300.86M | 305.24M | 264.81M | 222.84M |
| Net Income | 1.65B | 1.51B | 1.11B | 1.10B | 822.56M | 978.67M |
| EPS Basic | 6.27 | 5.83 | 4.54 | 4.4 | 3.35 | 3.72 |
| EPS Diluted | 6.26 | 5.82 | 4.53 | 4.4 | 3.34 | 3.71 |
| Basic Shares Outstanding | 248.65M | 248.65M | 248.65M | 248.65M | 248.65M | 248.65M |
| Diluted Shares Outstanding | 248.65M | 248.65M | 248.65M | 248.65M | 248.65M | 248.65M |
| Ebit | 2.16B | 1.92B | 1.45B | 1.43B | 1.10B | 1.22B |
| Ebitda | 2.34B | 2.11B | 1.64B | 1.61B | 1.28B | 1.36B |
| Net Income Continuous Operations | 2.12B | 1.88B | 1.41B | 1.40B | 1.08B | 1.20B |
| Minority Interests | -95.57M | -69.73M | 9.90M | -8.69M | 9.32M | -54.49M |
| Preferred Stock Dividends | 0 | 0 | 0 | 0 | 0 | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
